iX Biopharma: iXB 401 Novel semaglutide Sublingual Wafer Achieves 20X Higher Bioavailability Than Rybelsus In Preclinical Study.

19 Nov 2024 17:52

iX Biopharma Ltd. announced positive results from a single-dose pharmacokinetic study demonstrating that iXB 401, a novel semaglutide sublingual wafer, achieved significantly greater bioavailability, approximately 20 times higher, than the oral semaglutide tablet Rybelsus in a preclinical study conducted in 12 Sprague-Dawley rats...

Attachments: